USPTO serial 79360545
AMPHIPROTECH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 5, 2024
- Examiner
- CLYBURN, CARLA DIONNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AMPHIPROTECH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer and antibiotics; Medicines for human purposes for the prevention and treatment of liver diseases; Medicines for human purposes for the prevention and treatment of respiratory system disorders; Medicines for human purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Medicines for human purposes for the prevention and treatment of gastro-intestinal diseases; Medicines for human purposes for the prevention and treatment of immune system related diseases and disorders; Medicines for human purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Chemical preparations for pharmaceutical purposes for the treatment of infectious diseases, blood disorders, immune system related diseases, tumours, thyroid disease, cardiovascular and cerebrovascular diseases, inflammation and cancer; Biological preparations for medical purposes for the treatment of cancer, insomnia and heart disease; Biological preparations for medical purposes for the prevention and treatment of liver diseases; Biological preparations for medical purposes for the prevention and treatment of respiratory system disorders; Biological preparations for medical purposes for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Biological preparations for medical purposes for the prevention and treatment of gastro-intestinal diseases; Biological preparations for medical purposes for the prevention and treatment of immune system related diseases and disorders; Biological preparations for medical purposes for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Drugs, namely, insulin for the treatment of diabetes for medical purposes; Pharmaceutical preparations, namely, analgesics, antibiotics and aspirin; Pharmaceutical preparations for the prevention and treatment of liver diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Pharmaceutical preparations for the prevention and treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Medicines in form of tablet form for the treatment of cancer, insomnia and heart disease; Medicines in form of tablet form for the prevention and treatment of liver diseases; Medicines in form of tablet form for the prevention and treatment of respiratory system disorders; Medicines in form of tablet form for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Medicines in form of tablet form for the prevention and treatment of gastro-intestinal diseases; Medicines in form of tablet form for the prevention and treatment of immune system related diseases and disorders; Medicines in form of tablet form for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Biochemical medicines for the treatment of cancer, insomnia and heart disease; Biochemical medicines for the prevention and treatment of liver diseases; Biochemical medicines for the prevention and treatment of respiratory system disorders; Biochemical medicines for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases and diabetes; Biochemical medicines for the prevention and treatment of gastro-intestinal diseases; Biochemical medicines for the prevention and treatment of immune system related diseases and disorders; Biochemical medicines for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Capsules for medicines for the treatment of cancer, insomnia and heart disease; Capsules for medicines for the prevention and treatment of liver diseases; Capsules for medicines for the prevention and treatment of respiratory system disorders; Capsules for medicines for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases, diabetes; Capsules for medicines for the prevention and treatment of gastro-intestinal diseases; Capsules for medicines for the prevention and treatment of immune system related diseases and disorders; Capsules for medicines for the prevention and treatment of viral and infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cancer, tumors and cognitive disorders; Injectable medicinal solutions, namely, dermal fillers; Injectable medicinal solutions, namely, injectable contraceptives; Dietetic foods and beverages adapted for medical use; Dietetic preparations adapted for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Shanghai Puyou Biomedical Co., Ltd.
- Other trademarks owned by Shanghai Puyou Biomedical Co., Ltd.
- Other trademarks owned by Shanghai Puyou Biomedical Co., Ltd.
- Other trademarks in Class 005
- Similar marks named AMPHIPROTECH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 6, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 6, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 6, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 5, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 5, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 19, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 19, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 19, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 29, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 29, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 29, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 16, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 9, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 9, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 17, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 28, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 28, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 16, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 9, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 24, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 20, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 19, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |